(WTNH) — Johnson & Johnson announced Wednesday it has new evidence supporting a booster dose of its vaccine for people previously vaccinated with the single-dose J&J COVID-19 shot.
The roughly 10 percent of people who got the single-dose J&J COVID vaccine have been awaiting science and direction on if and when they will need a booster.
J&J said that the antibody responses generated by the one-dose shot were strong and stable through eight months after immunization.
New data from the studies demonstrate that the booster generated a “rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination.”
First responders’ and healthcare workers’ vaccine stamina were tested. They initially found that any decline in protection was not significant. But when the delta variant became the prominent strain that changed.
Dr. Martinello said, “Here they did see a significant decrease in how well that vaccine was working. That said, they did show that the vaccine was still as highly effective as before the delta variant.”
“We’re still waiting to hear what the CDC response is going to be for this new data and the data has not been published in the medical literature,” says Dr. Martinello.
Johnson & Johnson is working with the Food and Drug Administration (FDA) regarding the use of the booster.
The full study was published in the New England Journal of Medicine.
Earlier this week, Pfizer’s two-dose COVID vaccine was officially approved by the FDA. And, the Biden administration is preparing to roll out booster shots for people who got Pfizer and Moderna COVID shots starting the week of Sept. 20.